New combo aims to outsmart relapsed lung cancer

NCT ID NCT06681220

Recruiting now Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of two oral drugs, Stenoparib and Temozolomide, in people whose small cell lung cancer has returned after initial treatment. The trial uses a blood test (biomarker) to see who might benefit most from the combo, comparing it to the standard drug Lurbinectedin. About 166 participants will take part to first find the safest dose, then see if the combo improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stenoparib and Temozolomide combination
What this could lead to: If successful, this could offer a new, biomarker-guided treatment option for people with relapsed small cell lung cancer, potentially improving how long they live without their cancer growing.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits are uncertain. The drug combination may cause side effects or may not work better than the current standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT SMALL CELL LUNG CANCER RELAPSED SMALL CELL LUNG CANCER

Contacts and locations

Locations

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
RECRUITING

Philadelphia, Pennsylvania, 19104-4551, United States
Jesse Brown VA Medical Center, Chicago, IL
NOT_YET_RECRUITING

Chicago, Illinois, 60612, United States
Michael E. DeBakey VA Medical Center, Houston, TX
RECRUITING

Houston, Texas, 77030-4211, United States
Minneapolis VA Health Care System, Minneapolis, MN
NOT_YET_RECRUITING

Minneapolis, Minnesota, 55417-2309, United States
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
NOT_YET_RECRUITING

Omaha, Nebraska, 68105-1850, United States
Richard L. Roudebush VA Medical Center, Indianapolis, IN
RECRUITING

Indianapolis, Indiana, 46202-2884, United States
Robley Rex VA Medical Center, Louisville, KY
NOT_YET_RECRUITING

Louisville, Kentucky, 40206-1433, United States
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC
RECRUITING

Salisbury, North Carolina, 28144, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48105-2303, United States
VA Palo Alto Health Care System, Palo Alto, CA
RECRUITING

Palo Alto, California, 94304-1207, United States
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
RECRUITING

Pittsburgh, Pennsylvania, 15240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.